Exp Ther Med 20:[Related article:] 153, 2020; DOI:
10.3892/etm.2020.9292
Following the publication of this paper, it was
drawn to the authors' attention by a concerned reader that one of
the antibodies the authors used in their study was apparently
selected inappropriately: The antibody (cat. no. ab51243) that the
authors reported to have used for the apoptosis-associated protein
p16-INK4a was in fact specific for the protein known as P16 ARC (or
ARPC5), not as the authors had intended.
The authors replied to explain that they had made a
typing error in their paper. They confirmed that they did use the
correct antibody for the immunostaining experiments {cat. no.
ab108349; anti-CDKN2A/p16INK4a antibody [EPR1473]}, rather than
antibody cat. no. ab51243, and they were also able to show to the
Editorial Office the documents providing proof of the purchase of
the antibody.
Therefore, in the “Detection of cell
cycle-associated protein expression” subsection of the
Materials and methods section on p. 2, left-hand column, the
relevant text on line 10 should have read as follows (the changed
text is highlighted in bold): “...rabbit P16 (1:1,000
dilution; cat. no. ab108349; Abcam).
The authors are grateful to have been given the
opportunity to clarify this issue in their paper. All the authors
agree to the publication of this Corrigendum, and are grateful to
the Editor of Experimental and Therapeutic Medicine for
granting them the opportunity to publish this; moreover, they thank
the interested reader for drawing this matter to their attention,
and apologize to the readership for any inconvenience caused.
